Management of Dry Eye Disease with Artificial Tears Containing Hyaluronic Acid and Trehalose: A Narrative Review

Melissa Barnett,1 Michelle K Rhee,2 Kendall E Donaldson3 1Baker Optometry or Alpine Blue, Davis, CA, USA; 2Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Bascom Palmer Eye Institute of Plantation, Plantation, FL, USACorrespondence: Melissa Barnett, Baker Optometry, 2019 Anderson Road, Suite C, Davis, CA, 95616, USA, Tel +1-530-867-3451, Email [email protected]: Dry eye disease (DED) is a growing global public health concern. The market for over-the-counter artificial tears, the mainstay treatment for DED, is also experiencing growth, driven by the rising prevalence of the condition and advancements in therapeutic formulations. The treatment landscape for DED is rapidly evolving, and currently marketed artificial tears vary in their active ingredients, use of preservatives, and formulations. Therefore, it is imperative to understand the breadth of management options and the evidence base of formulations to inform treatment decisions and treatment guidelines. In our narrative review, we provide an overview of the development and regulation of artificial tear formulations in the United States. We evaluate their active ingredients, formulations, and use of preservatives. Increasingly, preservative-free formulations are being developed that contain combinations of well-established active ingredients. In this context, a key focus of the narrative review is to critically analyze the novel, preservative-free, multidose formulation of hyaluronic acid and trehalose in artificial tears. We highlight its formulation and mechanism of action and its involvement in autophagy regulation and inflammatory response. We describe the strong and growing evidence base supporting the effectiveness and safety of this combination formulation of artificial tears in managing DED, and we also describe its use in postcataract surgery and in the real world.Keywords: artificial tears, dry eye, trehalose, hyaluronic acid, combination, safety, efficacy

Authors

Institutions

Publication Details

Journal
SHILAP Revista de lepidopterología
Published
2026-01-01
Primary Topic
Ocular Surface and Contact Lens
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Management of Dry Eye Disease with Artificial Tears Containing Hyaluronic Acid and Trehalose: A Narrative Review

Rhee MK, Donaldson KE, Barnett M
SHILAP Revista de lepidopterología
Ocular Surface and Contact Lens
article

Management of Dry Eye Disease with Artificial Tears Containing Hyaluronic Acid and Trehalose: A Narrative Review

Rhee MK, Donaldson KE, Barnett M
article en

Abstract

Melissa Barnett,1 Michelle K Rhee,2 Kendall E Donaldson3 1Baker Optometry or Alpine Blue, Davis, CA, USA; 2Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Bascom Palmer Eye Institute of Plantation, Plantation, FL, USACorrespondence: Melissa Barnett, Baker Optometry, 2019 Anderson Road, Suite C, Davis, CA, 95616, USA, Tel +1-530-867-3451, Email [email protected]: Dry eye disease (DED) is a growing global public health concern. The market for over-the-counter artificial tears, the mainstay treatment for DED, is also experiencing growth, driven by the rising prevalence of the condition and advancements in therapeutic formulations. The treatment landscape for DED is rapidly evolving, and currently marketed artificial tears vary in their active ingredients, use of preservatives, and formulations. Therefore, it is imperative to understand the breadth of management options and the evidence base of formulations to inform treatment decisions and treatment guidelines. In our narrative review, we provide an overview of the development and regulation of artificial tear formulations in the United States. We evaluate their active ingredients, formulations, and use of preservatives. Increasingly, preservative-free formulations are being developed that contain combinations of well-established active ingredients. In this context, a key focus of the narrative review is to critically analyze the novel, preservative-free, multidose formulation of hyaluronic acid and trehalose in artificial tears. We highlight its formulation and mechanism of action and its involvement in autophagy regulation and inflammatory response. We describe the strong and growing evidence base supporting the effectiveness and safety of this combination formulation of artificial tears in managing DED, and we also describe its use in postcataract surgery and in the real world.Keywords: artificial tears, dry eye, trehalose, hyaluronic acid, combination, safety, efficacy

SHILAP Revista de lepidopterología
American Academy of Optometry (US), Ophthalmology Associates (United States) (US)
Good health and well-being
Openalex Percentile: Top 92%
Ocular Surface and Contact Lens
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.